Alexandre Xu-Vuillard

Randomised phase III trials of cancer prevention drugs: a systematic review and prediction of trial success

BACKGROUND: Pharmacological cancer risk reduction has received far less investment than therapeutic oncology and only a few agents have entered routine practice. Understanding the predictors of positive outcomes of previous trials and issues faced is critical to future developmen...